An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer’s disease

Treatment Combinations for Alzheimer’s Disease: Current And Future Pharmacotherapy Options

(2019) Jeffrey L. Cummings et al.   JOURNAL OF ALZHEIMERS DISEASE

Comparative efficacy and safety of therapy for the behavioral and psychological symptoms of dementia: a systemic review and Bayesian network meta-analysis

(2019) Boru Jin et al.   JOURNAL OF NEUROLOGY

Present Algorithms and Future Treatments for Alzheimer’s Disease

(2019) George T. Grossberg et al.   JOURNAL OF ALZHEIMERS DISEASE

Recent therapeutic strategies targeting beta amyloid and tauopathies in Alzheimer's disease

(2019) Yamini Madav et al.   BRAIN RESEARCH BULLETIN

Current and Future Treatments in Alzheimer's Disease

(2019) Alireza Atri   SEMINARS IN NEUROLOGY

Safety and tolerability of donepezil 23 mg with or without intermediate dose titration in patients with Alzheimer’s disease taking donepezil 10 mg: a multicenter, randomized, open-label, parallel-design, three-arm, prospective trial

(2019) Yun Jeong Hong et al.   Alzheimers Research & Therapy

Meta-Analysis of Randomized Controlled Trials on the Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer’s Disease

(2019) Dan-Dan Li et al.   Frontiers in Neuroscience

Proarrhythmic Effect of Acetylcholine-Esterase Inhibitors Used in the Treatment of Alzheimer’s Disease: Benefit of Rivastigmine in an Experimental Whole-Heart Model

(2019) Christian Ellermann et al.   Cardiovascular Toxicology

2018 Alzheimer's disease facts and figures

(2018)   Alzheimers & Dementia

Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease

(2018) Alireza Atri et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Alzheimer’s disease hypothesis and related therapies

(2018) Xiaoguang Du et al.   Translational Neurodegeneration

A review of clinical treatment considerations of donepezil in severe Alzheimer's disease

(2018) Aida Adlimoghaddam et al.   CNS Neuroscience & Therapeutics

Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation

(2017) Dana Mohammad et al.   Expert Opinion On Drug Safety

Discontinuation, Efficacy, and Safety of Cholinesterase Inhibitors for Alzheimer’s Disease: a Meta-Analysis and Meta-Regression of 43 Randomized Clinical Trials Enrolling 16 106 Patients

(2017) Lídia Blanco-Silvente et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Adherence and Tolerability of Alzheimer's Disease Medications: A Pragmatic Randomized Trial

(2017) Noll L. Campbell et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia

(2016) Jennifer Y.Y. Szeto et al.   Current Neuropharmacology

Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease

(2015) Bruno Dubois et al.   Alzheimers & Dementia

Skin reactions at the application site of rivastigmine patch (4.6 mg/24 h, 9.5 mg/24 h or 13.3 mg/24 h): a qualitative analysis of clinical studies in patients with Alzheimer's disease

(2015) G. Alva et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada

(2015) Thibault B. Ali et al.   PLoS One

Galantamine treatment in outpatients with mild Alzheimer's disease

(2014) U. Richarz et al.   ACTA NEUROLOGICA SCANDINAVICA

Which Rivastigmine Formula is Better for Heart in Elderly Patients With Alzheimer’s Disease

(2014) Ahmet Turan Isik et al.   American Journal of Alzheimers Disease and Other Dementias

Cardiac Safety of Donepezil in Elderly Patients with Alzheimer Disease

(2012) Ahmet Turan Isik et al.   INTERNAL MEDICINE

New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs

(2011) Salvatore Salomone et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Dementia Medications and Risk of Falls, Syncope, and Related Adverse Events: Meta-Analysis of Randomized Controlled Trials

(2011) Dae Hyun Kim et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

Potential Cardiotoxic Reaction Involving Rivastigmine and Beta-Blockers: A Case Report and Review of the Literature

(2010) Barbara Paulison et al.   Cardiovascular Toxicology

Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study

(2010) Martin R. Farlow et al.   CLINICAL THERAPEUTICS

Cholinesterase inhibition: is there evidence for disease-modifying effects?

(2009) Michael Shanks et al.   CURRENT MEDICAL RESEARCH AND OPINION

Optimal Dosing of Galantamine in Patients with Mild or Moderate Alzheimerʼs Disease

(2009) Stephen Aronson et al.   DRUGS & AGING

Effects of gender on response to treatment with rivastigmine in mild cognitive impairment: A post hoc statistical modeling approach

(2009) Steven Ferris et al.   Gender Medicine

Donepezil-Induced Adverse Side Effects of Cardiac Rhythm: 2 Cases Report of Atrioventricular Block and Torsade de Pointes

(2009) Atsushi Tanaka et al.   INTERNAL MEDICINE

Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer’s disease: a review

(2009) A. Kurz et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Progression from mild cognitive impairment to Alzheimerʼs disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment

(2009) Steven Ferris et al.   Pharmacogenetics and Genomics

Pharmacokinetics and Bioavailability of the Novel Rivastigmine Transdermal Patch Versus Rivastigmine Oral Solution in Healthy Elderly Subjects

(2008) Gilbert Lefèvre et al.   JOURNAL OF CLINICAL PHARMACOLOGY